» Articles » PMID: 32602823

Bat SARS-Like WIV1 Coronavirus Uses the ACE2 of Multiple Animal Species As Receptor and Evades IFITM3 Restriction TMPRSS2 Activation of Membrane Fusion

Overview
Date 2020 Jul 1
PMID 32602823
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Diverse SARS-like coronaviruses (SL-CoVs) have been identified from bats and other animal species. Like SARS-CoV, some bat SL-CoVs, such as WIV1, also use angiotensin converting enzyme 2 (ACE2) from human and bat as entry receptor. However, whether these viruses can also use the ACE2 of other animal species as their receptor remains to be determined. We report herein that WIV1 has a broader tropism to ACE2 orthologs than SARS-CoV isolate Tor2. Among the 9 ACE2 orthologs examined, human ACE2 exhibited the highest efficiency to mediate the infection of WIV1 pseudotyped virus. Our findings thus imply that WIV1 has the potential to infect a wide range of wild animals and may directly jump to humans. We also showed that cell entry of WIV1 could be restricted by interferon-induced transmembrane proteins (IFITMs). However, WIV1 could exploit the airway protease TMPRSS2 to partially evade the IFITM3 restriction. Interestingly, we also found that amphotericin B could enhance the infectious entry of SARS-CoVs and SL-CoVs by evading IFITM3-mediated restriction. Collectively, our findings further underscore the risk of exposure to animal SL-CoVs and highlight the vulnerability of patients who take amphotericin B to infection by SL-CoVs, including the most recently emerging (SARS-CoV-2).

Citing Articles

Cellular sialoglycans are differentially required for endosomal and cell-surface entry of SARS-CoV-2 in lung cell lines.

Siwak K, LeBlanc E, Scott H, Kim Y, Pellizzari-Delano I, Ball A PLoS Pathog. 2024; 20(12):e1012365.

PMID: 39625989 PMC: 11642992. DOI: 10.1371/journal.ppat.1012365.


Distinct pathways for evolution of enhanced receptor binding and cell entry in SARS-like bat coronaviruses.

Tse A, Acreman C, Ricardo-Lax I, Berrigan J, Lasso G, Balogun T PLoS Pathog. 2024; 20(11):e1012704.

PMID: 39546542 PMC: 11602109. DOI: 10.1371/journal.ppat.1012704.


Causes and Consequences of Coronavirus Spike Protein Variability.

Zech F, Jung C, Jacob T, Kirchhoff F Viruses. 2024; 16(2).

PMID: 38399953 PMC: 10892391. DOI: 10.3390/v16020177.


Kidney organoids reveal redundancy in viral entry pathways during ACE2-dependent SARS-CoV-2 infection.

Vanslambrouck J, Neil J, Rudraraju R, Mah S, Tan K, Groenewegen E J Virol. 2024; 98(3):e0180223.

PMID: 38334329 PMC: 10949421. DOI: 10.1128/jvi.01802-23.


The immune mechanism of the nasal epithelium in COVID-19-related olfactory dysfunction.

Chen S, Wang S Front Immunol. 2023; 14:1045009.

PMID: 37529051 PMC: 10387544. DOI: 10.3389/fimmu.2023.1045009.


References
1.
Gallagher T, Buchmeier M . Coronavirus spike proteins in viral entry and pathogenesis. Virology. 2001; 279(2):371-4. PMC: 7133764. DOI: 10.1006/viro.2000.0757. View

2.
Moen M, Lyseng-Williamson K, Scott L . Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs. 2009; 69(3):361-92. DOI: 10.2165/00003495-200969030-00010. View

3.
Millet J, Whittaker G . Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis. Virus Res. 2014; 202:120-34. PMC: 4465284. DOI: 10.1016/j.virusres.2014.11.021. View

4.
Ren W, Li W, Yu M, Hao P, Zhang Y, Zhou P . Full-length genome sequences of two SARS-like coronaviruses in horseshoe bats and genetic variation analysis. J Gen Virol. 2006; 87(Pt 11):3355-3359. DOI: 10.1099/vir.0.82220-0. View

5.
Lin T, Chin C, Everitt A, Clare S, Perreira J, Savidis G . Amphotericin B increases influenza A virus infection by preventing IFITM3-mediated restriction. Cell Rep. 2013; 5(4):895-908. PMC: 3898084. DOI: 10.1016/j.celrep.2013.10.033. View